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Regular alcohol consumption is common among American adults 
and has been associated with cardio-protection. Heavy alcohol 
consumption, however, can lead to adverse outcomes, such as 
neurological and renal damage, stroke, and premature death. 
Effects of long-term alcohol consumption have not been well 
studied in populations with diabetes, though it is estimated that at 
least 10% of Americans have diabetes. Complications of diabetes 
are common, and include damage to the nervous system, kidneys, 
and eyes, among others. Individuals living with diabetes who are 
heavy alcohol consumers may be at heightened risk for diabetic 
complications.  
DCCT (1983 – 1993) 
• 1,441 participants were randomized to one of two treatment
arms (intensive or conventional) at 29 clinical centers throughout
the United States and Canada.
 
• At randomization, participants were 13-39 years of age, insulin
dependent, and without any history of hypertension,
hypercholesterolemia, severe medical conditions, or severe
diabetic complications. DCCT participants were followed for a
mean of 6.5 years.
Current Analysis 
• Participants were excluded from analysis if they were under 18
years of age at baseline (n=1,246). Analyses were conducted at
baseline, DCCT follow-up year 5, and DCCT closeout so long as
the outcome and predictor variables in each of the analyses
were not missing.
• Independent variable: alcohol consumption, collected by self-
report during the DCCT annual visit through an interview-
administered questionnaire.
• Dependent variables: retinopathy, nephropathy, and neuropathy
(analyzed as absent/present) at each of the 3 time points.
• Potential confounding variables included gender, hemoglobin
A1c (HbA1c) levels, smoking status, education level, marital
status, LDL cholesterol level, treatment status (intensive vs.
conventional), and age.
• Though most results of this analysis were not statistically significant, trends in ORs were consistent with the
current literature. Non-heavy alcohol drinking did not substantially impact development of renal, retinal, or
neurological complications within the DCCT cohort, which is likely due to the near-identical HbA1c values
between drinkers and non-drinkers throughout the study.
• Limitations of this analysis include:
o Small sample size  (n=17) of heavy drinkers, preventing analysis with this group
o Ethnically non-diverse sample (97% white non-Hispanic)
o Lack of distinction between non-drinkers and former drinkers
o Probable underreporting of drinking behaviors
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• Due to small sample size of heavy drinkers at baseline (n=17), formal statistical comparisons concerning this
group were not feasible.
• HbA1c did not vary between drinkers and non-drinkers throughout the DCCT, regardless of treatment group
(Figure 1, Figure 2) leading to non-significant odds (p>.05) of developing neuropathy, retinopathy, and
nephropathy at baseline, year 5, and closeout.
• Slightly protective effects of drinking demonstrated that drinkers at year 5 were 56% less likely have
retinopathy at year 5 (OR=0.44 (0.18, 1.05)) (Table 1), and that drinkers at closeout were 30% less likely to have
neuropathy at closeout (OR=0.69 (0.47, 1.00)) compared to non-drinkers (Table 2).
• All other analyses did not yield statistically significant results, including analysis of drinking as a continuous
variable.
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No. of events (%) 
 Drinkers 
No. of events (%) 
Non-Drinkers 
Unadjusted OR Adjusted OR* 
N=756 N=454 




No. of events (%) 
 Drinkers 
No. of events (%) 
Non-Drinkers 
Unadjusted OR Adjusted OR* 
N=602 N=343 
 Year 5  26 (4)  8 (2) 0.53 (0.24, 1.18) 0.44 (0.18, 1.05) 
N=602 N=343 
 Closeout  30 (5) 13 (4) 0.75 (0.39, 1.46) 0.63 (0.31, 1.31) 
Odds of Retinopathy at Year 5 and Closeout Predicted by 
Drinking Status at Year 5 
Odds of Neuropathy at Closeout Predicted by 
Drinking Status at Closeout 
METHODS 
*Odds ratios were adjusted for age, sex, baseline smoking status, baseline marital status, baseline education, baseline HbA1c,
baseline LDL, and treatment group (intensive vs. conventional). 
o Conventional treatment arm: participants administered one
or two insulin injections daily (did not adjust insulin dosage
daily), monitored blood glucose/urine daily, were educated
about diet and exercise, and came into the clinical centers for
evaluation every three months.
o Intensive treatment arm: participants administered insulin
three or more times daily by injection or external pump.
Dosage was adjusted at least four times per day, and they
were seen at their clinical center monthly.
o Participants were considered “drinkers” if they responded
that they consumed at least one alcoholic beverage per
week in the last 12 months at each of the 3 separate time
points.
